| Literature DB >> 28577365 |
Shristi Raut1, Kishor Bajracharya2, Janak Adhikari3, Sushama Suresh Pant2, Bipin Adhikari4.
Abstract
BACKGROUND: Multidrug resistant Staphylococcus aureus is common in both tertiary and primary health care settings. Emergence of methicillin resistance in S. aureus (MRSA) along with macrolide, lincosamide, streptogramin B (MLSB) has made treatment of Staphylococcal infection more challenging. The main objective of this study was to detect MRSA, MLSB (inducible; MLSBi and constitutive; MLSBc) resistant S. aureus using phenotypic methods and to determine their antibiogram.Entities:
Keywords: Cefoxitin; D-zone test; MRSA; Staphylococcus aureus
Mesh:
Substances:
Year: 2017 PMID: 28577365 PMCID: PMC5457603 DOI: 10.1186/s13104-017-2515-y
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Variables in relation to MRSA and MSSA (n = 133)
| Variables | MRSA (n = 58) | MSSA (n = 75) | p value |
|---|---|---|---|
| Number (%) | Number (%) | ||
| Age (years) | |||
| <10 | 26 (49.1) | 27 (50.9) | 0.452 |
| 11–30 | 16 (36.4) | 28 (63.6) | |
| >30 | 16 (44.4) | 20 (55.6) | |
| Sex | |||
| Male | 33 (52.4) | 30 (47.6) | 0.057 |
| Female | 25 (35.7) | 45 (64.3) | |
| Source of samples | |||
| Ward | 27 (48.2) | 29 (51.8) | 0.307 |
| OPD | 14 (33.3) | 28 (66.7) | |
| ER | 4 (36.4) | 7 (63.6) | |
| ICU | 13 (54.2) | 11 (45.8) | |
| Duration of hospital stay | |||
| No hospital stay | 34 (38.6) | 54 (61.4) | 0.253 |
| <48 h | 9 (50.0) | 9 (50.0) | |
| >48 h | 15 (55.6) | 12 (44.4) | |
| Type of samples | |||
| Blood | 32 (49.2) | 33 (50.8) | 0.463 |
| Pus | 13 (33.3) | 26 (66.7) | |
| Swab | 6 (42.9) | 8 (57.1) | |
| Others | 7 (46.7) | 8 (53.3) | |
| Patient’s conditions | |||
| Central line | |||
| Opened | 21 (56.8) | 16 (43.2) | 0.079 |
| Not opened | 37 (38.5) | 59 (61.5) | |
| On urinary catheter | |||
| Yes | 11 (68.8) | 5 (31.3) | 0.057 |
| No | 47 (40.2) | 70 (59.8) | |
| On ventilator | |||
| Yes | 4 (57.1) | 3 (42.9) | 0.699 |
| No | 54 (42.9) | 72 (57.1) | |
| ICU stay | |||
| Yes | 10 (62.5) | 6 (37.5) | 0.116 |
| No | 48 (41.0) | 69 (69.0) | |
| ET/tracheostomy/NG tube | |||
| Yes | 4 (44.4) | 5 (55.6) | 1 |
| No | 54 (43.5) | 70 (56.5) | |
| Surgery before infection | |||
| Yes | 8 (61.5) | 5 (38.5) | 0.24 |
| No | 50 (41.7) | 70 (58.3) | |
| Skin lesions | |||
| Yes | 11 (44.0) | 14 (56.0) | 1 |
| No | 47 (43.5) | 61 (56.5) | |
| Enteral feeding | |||
| Yes | 5 (50.0) | 5 (50.0) | 0.744 |
| No | 51 (42.1) | 70 (57.9) | |
| History of taking antibiotics | |||
| Yes | 24 (52.2) | 22 (47.8) | 0.198 |
| No | 34 (39.1) | 53 (60.9) | |
Ward In Patient Department where patients are admitted for treatment, OPD Out Patient Department, ER emergency, ICU Intensive Care unit, ET tube endotracheal tube, NG tube naso-gastric tube
Antibiotic profile of MRSA and MSSA (n = 133)
| Antibiotic | MRSA (n = 58) | MSSA (n = 75) | p value |
|---|---|---|---|
| Number (%) | Number (%) | ||
| Oxacillin | |||
| Sensitive | 15 (16.9) | 74 (83.1) | <0.001 |
| Resistant | 43 (97.7) | 1 (2.3) | |
| Penicillin | |||
| Sensitive | 0 | 10 (100) | 0.005 |
| Resistant | 58 (47.2) | 65 (52.8) | |
| Ciprofloxacin | |||
| Sensitive | 28 (31.5) | 61 (68.5) | <0.001 |
| Resistant | 30 (68.2) | 14 (31.8) | |
| Cotrimoxazole | |||
| Sensitive | 28 (30.8) | 63 (69.2) | <0.001 |
| Resistant | 30 (71.4) | 12 (28.6) | |
| Gentamicin | |||
| Sensitive | 33 (33.3) | 66 (66.7) | <0.001 |
| Resistant | 25 (73.5) | 9 (26.5) | |
| Amikacin | |||
| Sensitive | 48 (39.0) | 75 (61.0) | <0.001 |
| Resistant | 10 (100) | 0 | |
| Tetracycline | |||
| Sensitive | 46 (38.7) | 73 (61.3) | 0.001 |
| Resistant | 12 (85.7) | 2 (14.3) | |
| Erythromycin | |||
| Sensitive | 18 (26.1) | 51 (73.9) | <0.001 |
| Resistant | 40 (62.5) | 24 (37.5) | |
| Clindamycin | |||
| Sensitive | 37 (37.75) | 66 (62.25) | 0.001 |
| Resistant | 21 (70.0) | 9 (30.0) | |
| Vancomycin | |||
| Sensitive | 55 (42.3) | 75 (57.7) | 0.08 |
| Resistant | 3 (100) | 0 | |
| Linezolid | |||
| Sensitive | 58 (43.6) | 75 (56.4) | |
| Resistant | 0 | 0 | |
Antibiotic profile of MLSBi, MLSBc and ERY, CL sensitive phenotype (n = 133)
| Antibiotics | MLSB | Sensitive phenotype (69) | p value | |
|---|---|---|---|---|
| MLSBi (34) | MLSBc (30) | |||
| Oxacillin | ||||
| Sensitive | 20 (22.5) | 13 (14.6) | 56 (62.9) | 0.001 |
| Resistant | 14 (31.8) | 17 (38.6) | 13 (29.5) | |
| Penicillin | ||||
| Sensitive | 1 (10) | 2 (20) | 7 (70) | 0.419 |
| Resistant | 33 (26.8) | 28 (22.8) | 62 (50.4) | |
| Ciprofloxacin | ||||
| Sensitive | 22 (24.7) | 13 (14.6) | 54 (60.7) | 0.003 |
| Resistant | 12 (27.3) | 17 (38.6) | 15 (34.1) | |
| Cotrimoxazole | ||||
| Sensitive | 20 (22.0) | 14 (15.4) | 57 (62.6) | 0.001 |
| Resistant | 14 (33.3) | 16 (38.1) | 12 (28.6) | |
| Gentamicin | ||||
| Sensitive | 26 (26.3) | 17 (17.2) | 56 (56.6) | 0.035 |
| Resistant | 8 (23.5) | 13 (38.2) | 13 (38.2) | |
| Amikacin | ||||
| Sensitive | 31 (25.2) | 24 (19.5) | 68 (55.3) | 0.005 |
| Resistant | 3 (30.0) | 6 (60.0) | 1 (10.0) | |
| Tetracycline | ||||
| Sensitive | 28 (23.5) | 23 (19.3) | 68 (57.1) | 0.001 |
| Resistant | 6 (42.9) | 7 (50) | 1 (7.1) | |
| Erythromycin | ||||
| Sensitive | 0 | 0 | 69 (100) | <0.001 |
| Resistant | 34 (53.1) | 30 (46.9) | 0 | |
| Clindamycin | ||||
| Sensitive | 34 (33) | 0 | 69 (67) | <0.001 |
| Resistant | 0 | 30 (100.0) | 0 | |
| Vancomycin | ||||
| Sensitive | 34 (26.2) | 27 (20.8) | 69 (53.1) | 0.005 |
| Resistant | 0 | 3 (100) | 0 | |
| Linezolid | ||||
| Sensitive | 34 (25.6) | 30 (22.6) | 69 (51.9) | <0.001 |
| Resistant | 0 | 0 | 0 | |
MLSB in relation to MRSA (n = 133)
| Variables | MRSA (58) | MSSA (75) | p value |
|---|---|---|---|
| MLSBi | 19 (55.9) | 15 (44.1) | <0.001 |
| MLSBc | 21 (70.0) | 9 (30.0) | |
| Sensitive phenotype | 18 (26.1) | 51 (73.9) |